FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

on, D.C. 20549	OMB APPROVAL
	i—————————————————————————————————————

OMB Number:	3235-0287					
Estimated average burd	en					
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Johnston David</u>					2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 150 INDUSTRIAL ROAD				09/	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2006									SVP, I				
(Street) SAN CARLOS CA 94070 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 09/06/2006								Line)	S. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(0.0)			le I - Nor	n-Deriv	vativ	e Se	curities	S Ac	quired, D	Disp	osed o	of, or Be	nefic	cially	/ Owned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)					4 and Securitie Benefici		es Formally (D) (Following (I) (I	Ownership orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	/	Amount	Amount (A) or (D)			Transaction(s) (Instr. 3 and 4)			, ,	
		-	Γable II -						uired, Dis , options						Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution I if any (Month/Day	Date,	4. Transa Code (8)			ve es d	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amo or Num of Shai	ber				
Restricted Stock Unit	\$0.01	09/01/2006			A		10,000		(1)		(2)	Common Stock1	10,0	000	\$0.01	18,000	D	

Explanation of Responses:

1. The shares of Common Stock are issued upon the vesting of restricted stock units granted to the holder. The restricted stock units (RSUs) vest based on the Company achieving certain corporate performance milestones as follows: 1/5th of the RSUs vest based on achievement of a corporate goal related to the total number of Exubera Inhalers shipment; 2/5th vest based on achievement of a corporate goal related to Exubera quarterly royalty revenue; and 2/5th vest based on achievement of a corporate goal related to regulatory progress of the Companys proprietary products programs.

2. Not Applicable.

/s/ David Johnston 03/13/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.